monetization_vector
Recurring licensing fees and profit sharing; per-unit product sales
Medium
SEC-10K 0000872589-26-000008
pricing_architecture
Negotiated & tiered rebate-based
Medium
SEC-10K 0000872589-26-000008
revenue_model_type
Product sales & collaboration profit sharing
Medium
SEC-10K 0000872589-26-000008
customer_acquisition_metric
Direct sales force for U.S. EYLEA/EYLEA HD; Sanofi/Bayer co-promotion internationally; PBM formulary placement; copay assistance programs for patient affordabil
Medium
SEC-10K 0000872589-26-000008
customer_segment_primary
Enterprise (healthcare systems, payors, PBMs)
Medium
SEC-10K 0000872589-26-000008
customer_segment_secondary
Institutional (Medicaid, Medicare, government programs)
Medium
SEC-10K 0000872589-26-000008
business_model_type_primary
Integrated biopharmaceutical manufacturer & commercializer
Medium
SEC-10K 0000872589-26-000008
business_model_type_secondary
Licensing & royalty partner
Medium
SEC-10K 0000872589-26-000008
supply_chain_dependency
High
Medium
SEC-10K 0000872589-26-000008
headcount_cost_structure
Linear
Medium
SEC-10K 0000872589-26-000008
geographic_footprint
Predominantly U.S.; growing international through collaborators
Medium
SEC-10K 0000872589-26-000008
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
howey_test_risk_index
Low
Medium
SEC-10K 0000872589-26-000008
antitrust_exposure_flag
No
Medium
SEC-10K 0000872589-26-000008
data_sovereignty_risk
Moderate
Medium
SEC-10K 0000872589-26-000008
vendor_lock_dependency_score
High
Medium
SEC-10K 0000872589-26-000008
pricing_power_rating
Moderate
Medium
SEC-10K 0000872589-26-000008
network_effect_present
No
Medium
SEC-10K 0000872589-26-000008
switching_cost_profile
High
Medium
SEC-10K 0000872589-26-000008
asset_efficiency_ratio
12.9% Return on Assets (Excellent)
High
SEC-XBRL
recession_resistance_tier
Mixed
Medium
SEC-10K 0000872589-26-000008
interest_rate_sensitivity
Moderate
Medium
SEC-10K 0000872589-26-000008
geopolitical_supply_exposure
Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.
Medium
GICS-commodity-overlay-v2
marginal_cost_of_growth
Sublinear
Medium
SEC-10K 0000872589-26-000008
international_expansion_readiness
Moderate
Medium
SEC-10K 0000872589-26-000008
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.25 (HIL — ~25% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v2
commodity_exposure_profile
Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.
Medium
GICS-commodity-overlay-v2
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
sec_cik
0000872589
High
SEC-EDGAR
ticker
REGN
High
SEC-EDGAR
churn_vulnerability_index
High
Medium
SEC-10K 0000872589-26-000008
Filings_Dog_Scope
antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,churn_vulnerability_index,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,data_sovereignty_risk,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,marginal_cost_of_growth,monetization_vector,network_effect_present,pricing_architecture,pricing_power_rating,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,supply_chain_dependency,switching_cost_profile,vendor_lock_dependency_score
High
SEC-10K 0000872589-26-000008
insider_buys_6m
0
High
SEC-Form4 0001663758-26-000002..0001104659-26-039613
insider_sells_6m
27
High
SEC-Form4 0001663758-26-000002..0001104659-26-039613
insider_net_shares_6m
-4346
High
SEC-Form4 0001663758-26-000002..0001104659-26-039613
insider_last_transaction_date
2026-09-03
High
SEC-Form4 0001663758-26-000002..0001104659-26-039613
Insider_Dog_Checked
2026-10-03T13:57|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m
High
SEC-Form4 registry
activist_13d_count_1y
0
High
SEC-13D/G registry, subject-verified
blockholder_13g_count_1y
2
High
SEC-13D/G registry, subject-verified
activist_last_13d_date
none in window
High
SEC-13D/G registry, subject-verified